NASDAQ:ABVC ABVC BioPharma (ABVC) Stock Price, News & Analysis $0.55 -0.02 (-3.07%) (As of 10:38 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About ABVC BioPharma Stock (NASDAQ:ABVC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ABVC BioPharma alerts:Sign Up Key Stats Today's Range$0.55▼$0.5950-Day Range$0.47▼$0.7452-Week Range$0.41▼$2.45Volume46,608 shsAverage Volume868,151 shsMarket Capitalization$7.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Read More… This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here ABVC BioPharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks15th Percentile Overall ScoreABVC MarketRank™: ABVC BioPharma scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ABVC BioPharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ABVC BioPharma is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ABVC BioPharma is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioABVC BioPharma has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.77% of the float of ABVC BioPharma has been sold short.Short Interest Ratio / Days to CoverABVC BioPharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABVC BioPharma has recently increased by 34.83%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldABVC BioPharma does not currently pay a dividend.Dividend GrowthABVC BioPharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.77% of the float of ABVC BioPharma has been sold short.Short Interest Ratio / Days to CoverABVC BioPharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABVC BioPharma has recently increased by 34.83%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.73 News SentimentABVC BioPharma has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ABVC BioPharma this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ABVC BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders11.90% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.38% of the stock of ABVC BioPharma is held by institutions.Read more about ABVC BioPharma's insider trading history. Receive ABVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABVC Stock News HeadlinesABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational MilestonesNovember 14, 2024 | finance.yahoo.comRAKUS Co., Ltd. Reports Strong Growth in 2024November 14, 2024 | msn.comJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.November 21, 2024 | Priority Gold (Ad)ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic PartnersOctober 22, 2024 | globenewswire.comABVC BioPharma (NASDAQ:ABVC) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic AchievementsAugust 15, 2024 | globenewswire.comABVC BioPharma's CEO Discusses New Drug Development and AI IntegrationJuly 19, 2024 | finance.yahoo.comImmunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50MMay 24, 2024 | finance.yahoo.comSee More Headlines ABVC Stock Analysis - Frequently Asked Questions How have ABVC shares performed this year? ABVC BioPharma's stock was trading at $1.16 at the beginning of 2024. Since then, ABVC stock has decreased by 52.6% and is now trading at $0.55. View the best growth stocks for 2024 here. How were ABVC BioPharma's earnings last quarter? ABVC BioPharma, Inc. (NASDAQ:ABVC) posted its earnings results on Monday, April, 3rd. The company reported ($1.50) EPS for the quarter, topping analysts' consensus estimates of ($1.90) by $0.40. The firm had revenue of $0.59 million for the quarter, compared to analysts' expectations of $0.03 million. ABVC BioPharma had a negative trailing twelve-month return on equity of 104.94% and a negative net margin of 1,619.65%. When did ABVC BioPharma's stock split? ABVC BioPharma shares reverse split on Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did ABVC BioPharma IPO? ABVC BioPharma (ABVC) raised $7 million in an IPO on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at a price of $6.25 per share. How do I buy shares of ABVC BioPharma? Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ABVC BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ABVC BioPharma investors own include Meta Platforms (META), NIO (NIO), ObsEva (OBSV), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and Walt Disney (DIS). Company Calendar Last Earnings4/03/2023Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVC CUSIPN/A CIK1173313 Webwww.abvcpharma.com Phone(510)-668-0881FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,520,000.00 Net Margins-1,619.65% Pretax Margin-1,699.98% Return on Equity-104.94% Return on Assets-56.81% Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual Sales$150,000.00 Price / Sales49.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.02 per share Price / Book0.56Miscellaneous Outstanding Shares12,980,000Free Float11,431,000Market Cap$7.36 million OptionableNot Optionable Beta0.82 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:ABVC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.